• Flaws in the U.S. health-care system revealed during COVID-19 pandemic
• Lack of medication adherence can lead to serious issues, including worsening of disease, possible death and increased costs
• United Medical offers solutions for poor patient-physician communication and inadequate medication knowledge

The COVID-19 pandemic has revealed flaws in the U.S. health-care system, including flaws that require patients and caregivers to take a more active and educated role. United Medical Equipment Business Solutions Network (“UME”) provides reliable resources and solutions to help providers work more proficiently, health-care systems work smarter, and patients live healthier lives.

“This pandemic is a watershed moment in American history, one we must seize upon to fix the most glaring problems in our health system. We can’t ignore one health crisis for the sake of another,” wrote American Medical Association CEO and executive VP James L. Madara, MD, in a recent article (https://ibn.fm/ixqFL).

A few of the flaws that Madara points out are unequal treatment based on location, ethnicity, affordability and access to health insurance. He calls for collaboration to disrupt the status quo and create a new, affordable, efficient and accessible system for all. However, he notes, many obstacles interfere with patient care.

Communication and a lack of education around the medicines administered play a large part in failed care plans, dosage errors, no-adherence and readmittance to hospitals. Not every patient has easy access to needed education, which is something UME is working to change.

When patients and their doctors communicate clearly and openly with one another, the better the level and execution of a care plan occurs. When communication is clear, the patient or caregiver better understands the health condition and the treatment options. Proper education around all over-the-counter and prescribed doses is essential to avoid missed, skipped or willfully ignored care plans.

Medication management is an essential part of any treatment plan. When a patient or caregiver understands the purpose, dosage, side effects and other unique qualities of the medications being prescribed, they have a higher success rate of follow through. Aging individuals need caregivers who also have access to this education, whether those caregivers are able to attend doctor appointments or not.

Collaboration between a patient and physician is essential to improve the patient’s health. The physician needs to know all medications being taken, including over-the-counter, herbal and alternatives, because they may interact with what is prescribed. The patient needs to be informed about what they are taking, as well as why and how the medications work.

A lack of adherence can lead to serious problems that include a worsening of disease, possible death and increased costs to both the patient and the overall health-care system. Poor provider-patient communication and inadequate knowledge about a drug are two large barriers in medication adherence (https://ibn.fm/MVVWn). United Medical has developed a solution to address these barriers: a free medication management app available for download on the Apple App Store and Google Play.

The free seven-day trial version of the Medication Management app has a medication dictionary with up-to-date information on medications. The dictionary provides an image and description of the physical drug as well as an overview, side effects to look for, interactions with food and other drugs, and more. The app also comes with a pill identifier and converters for weight, temperature, volume, height and dosage. The company’s newest, highly asked for feature — Medication Log-Reminder — allows users to log all their medications in one convenient location and set reminders to take their medications. The app is protected by HIPAA compliance for PHI. Subscriptions are also available that allow the user to access telehealth and additional services for a small monthly fee.

For more information, visit the company’s website at www.UnitedMedSolutions.com.

NOTE TO INVESTORS: The latest news and updates relating to United Medical Equipment are available in the company’s newsroom at https://ibn.fm/UnitedMed

• HYB Holding Corp.’s subsidiary, Mediscan Inc., offers technology that can turn 2D images from a portable ultrasound machine into digital 3D images to provide better diagnosis and more accurate internal trauma views
• Mediscan’s technology has multiple applications in lung, cardiac and musculoskeletal imaging and related applications
• A portable ultrasound scanner equipped with the Mediscan application can help detect and diagnose lung and cardiac tissue damage in COVID-19 patients, who cannot undergo regular imaging procedures while contagious
• Mediscan recently filed a provisional patent application with the United States Patent and Trademark Office for a System Method, Apparatus, and Computer Program Product for Ultrasonic Clinical Decision Support
• Global demand for enhanced diagnostic imaging has increased due to the urgency of providing early diagnosis in patients
• Mediscan technology is available through a software-as-a-service model, helping health care providers reduce costs and increase patient satisfaction by providing speedier, effective imaging services
• The company’s management team come from legal, business and technology backgrounds, giving Mediscan access to a broad array of applicable knowledge

HYB Holding (OTC: HYBG), through its Mediscan Inc. subsidiary, created a cloud-based software for ultrasound technology that reconstructs the analog two-dimensional grayscale visual image into a digital three-dimensional, high-definition quantifiable format. The Mediscan software application dramatically increases the medical professional’s ability to use existing ultrasound devices at the point of care to derive meaningful data-driven clinical evaluations of a patient’s pathology or trauma, facilitate support for treatment options, monitor the patient’s ongoing progress or regress, and document compliance with required protocols and procedures. The Mediscan application also integrates with all popular EMR systems. HYB Holding Corp. acquired all of Mediscan’s capital stock in a reverse acquisition transaction on November 13, 2020. On November 23, 2020, the shareholders of HYB Holding Corp. consented to a resolution changing its name to Healthtech Solutions Inc. The company’s operational focus for the immediate future will be on Mediscan’s continuing research and development of imaging, development of other medical solutions, and making strategic investments. Mediscan Technology Mediscan software transforms an ultrasound analog 2D grayscale image into a digital 3D HD format. When paired with a portable ultrasound machine, the software application can enable these detailed and quantifiable scans by on-the-scene medical professionals, such primary care physicians, specialists and technical support staff, as well as sports trainers, emergency medical services (“EMS”) personnel, and technicians in isolation wards and emergency rooms. Once an image has been captured in 2D, it is converted using a cloud-based software application process – a process that takes approximately one minute. The completed 3D image is viewed on the medical professional’s computer monitor, pad or smartphone at the point of service. This technique can generate 3D medical images of different organs, such as the heart, lungs, tendons, skin and nerves. This cloud-based software application for ultrasound devices is easy to use anywhere there is an internet connection. The application provides the convenience of point of care ultrasound with the image quality of CT or X-ray and the safety of very expensive MRI technology. For patients, it provides a convenient and comfortable medical experience. Mediscan has filed two patent applications with the United States Patent and Trademark Office, both for a System Method, Apparatus, and Computer Program Product for Ultrasonic Clinical Decision Support (https://ibn.fm/lpImS). The technology will initially be available as medical software-as-a-service (“SaaS”), resulting in cost-efficiency. The SaaS model eliminates the customer’s need for external hardware and software solutions, as well as technical maintenance. The SaaS model is already widely used in the health care industry, most notably for clinical information systems and supply chain management, revenue cycle management and billing. Benefits include increased patient and physician satisfaction, lower operational costs, better workflows and more. Per company data, the Mediscan system is fast and efficient, which could generate a significant cost reduction. Health and Wellness Applications Mediscan’s technology has shown success in musculoskeletal (“MSK”), lung and cardiac imaging, enabling rapid pathology evaluation. Scanning the lung and or the MSK sub-system, the application directly images the target area, saves it as a reference, and then compares it to previous images, helping to determine if the patient is progressing or regressing. The cardiac application combines imaging with a therapy system that detects and classifies cardiac myopathy conditions via an “entrainment” process similar to that used in treating tachycardia. This application also features a comparison function where the latest imagery is interpreted against previous vetted cardiac images to detect progression or regression. Mediscan’s technology can also be utilized on the wellness market for diagnostics and support in a wide range of situations, such as sports injuries, physical therapy and dermatological indications. COVID-19 Applications COVID-19 causes complications with patients’ cardiovascular and pulmonary systems. Mediscan’s technology could help meet the growing need for advanced diagnostic and monitoring imaging at the point of care. Portable ultrasounds equipped with Mediscan’s application are a flexible and easy-to-use solution for health care providers to evaluate, triage and diagnose COVID-19 effects on contagious patients in isolation where MRI, CT or PET Scans are not accessible. With this technology, health care providers can easily detect lung lesions or heart muscle shredding, which often appear in patients with COVID-19. Diagnostic Imaging Market Outlook With the increasing demand for early diagnosis and a widening scope of clinical applications, any promising technological advancements in the field constitute a significant investment opportunity. The global market is also being driven by technological advances in the diagnostic imaging industry. As standard ultrasound 2D greyscale images are generally the norm, and 3D imaging typically requires the use of CT, PET, MRI or X-ray technology, Mediscan’s application could have a dramatic impact on the medical imaging industry, meeting the need for imaging equipment and devices that can generate human anatomy data in 3D. The global market for diagnostic imaging was estimated at approximately $100 billion in 2016 (https://ibn.fm/xtInK) and was expected to grow steadily, creating a promising opportunity for Mediscan to distribute its technology and achieve its mission as a developer and distributor of medical imaging solutions designed for both long-term care and acute and emergency medical services. Management Team David Rubin is the Chairman and CEO of HYB Holding Corp. Mr. Rubin has been in the financial services business for over 20 years. Concurrently, he is also the CEO of Capital Stack LLC and CEO of eProdigy Financial LLC. Rubin attended Kingsborough Community College from 1985 to 1988. Manuel Iglesias is the President and a Director of HYB Holding Corp. Mr. Iglesias has practiced law since 1980, specializing in business law, merger and acquisitions, securities and health care. Mr. Iglesias served as President, CEO and a board member of Hygea Holdings Corp., which provided primary care medical services throughout Florida and Georgia. He served as the National Chairman of the Republican National Lawyers Association in 2019 and 2020. Mr. Igleisias was awarded his MBA degree from the University of Chicago in 1981, a Juris Doctorate from the University of Chicago in 1979, and a BS in Foreign Service from Georgetown University in 1976. Denis Kleinfeld is a Director of HYB Holdings Corp. and General Counsel and a Director of Mediscan Inc. Mr. Kleinfeld has extensive experience in business planning and regulatory compliance. Mr. Kleinfeld is a renowned expert in international tax and estate planning law. Kleinfeld received his Juris Doctorate from the Loyola University of Chicago School of Law in 1970. Richard F. Parker is the Chief Research Officer of Mediscan Inc. He developed the technology that is the foundation of Mediscan’s business plan. Before he joined Mediscan, Mr. Parker was employed as an engineer and business executive for 37 years. Previously, he was President and Chief Technology Officer of CytoWave LLC. Mr. Parker was awarded a patent for technology that supported a Method and Apparatus for Generating a Therapeutic Magnetic Waveform. During the past 10 years, Mr. Parker has published 14 papers and made numerous presentations focused on magnetic imaging and treatment of sports and equine injuries. He obtained his MSEE degree from the Georgia Institute of Technology in 1971. For more information, visit the company’s website at www.MyMediScan.com. NOTE TO INVESTORS: The latest news and updates relating to HYBG are available in the company’s newsroom at https://ibn.fm/HYBG

• CBD products in oil-based form have compromised bioavailability, according to experts
• CNSC’s Xceptol CBD products created with proprietary CiBiDinol technology that addresses absorption issues for superior efficacy
• Third-party Xceptol testing shows 300% increased gut absorption, 400% increased skin penetration when compared to mainstream CBD oil products

Growing in popularity in a myriad of markets, cannabidiol (“CBD”) is a phytocannabinoid that can mimic natural endocannabinoids in the human body for various therapeutic effects. Growing awareness around the use of oil-based CBD has led to skyrocketing popularity among the mainstream public despite bioavailability concerns among healthcare professionals and doctors (https://ibn.fm/d0Kab). CannAssist International (OTCQB: CNSC), a biotechnological pharmaceutical company and owner of Xceptor Labs, has sought to address this issue through its CiBiDinol technology that increases absorbability, bioavailability and shelf life for all CBD products marketed under its Xceptol consumer brand. Bioavailability – the amount of a substance required to produce a response in the human body – is a growing concern among health professionals and consumers interested in the use of CBD oil for the treatment of various health conditions. Higher bioavailability typically translates to increased effectiveness, leading many CBD users and practitioners to believe that most CBD products’ oil-based nature may reduce absorption because oil and water do not mix. “Cannabinoids are fat-loving molecules and have to traverse a cellular environment that is aqueous or watery,” said Dr. Patricia Frye, a member of the Society of Cannabis Clinicians. According to Dr. Frye, the effects of oil-based cannabis can be delayed when bioavailability is limited. CNSC’s CiBiDinol technology directly addresses this issue through a proprietary process that combines CBD molecules with penetration-enhancing cyclodextrin, which covers the surface of the molecule rendering it water dispersible. Marketed under the Xceptol consumer brand, CBD products created using CiBiDinol technology promise increased efficacy, absorption and bioavailability for superior results per dose. Third-party testing confirmed a 300% increase in gut absorption rate and a 400% increase in skin penetration compared to regular oil-based CBD (https://ibn.fm/8Cqm0). CNSC is taking CiBiDinol technology further into mainstream medicine through several regulatory moves, including a submission to the FDA’s bulk drug substance program along with a submission for safety evaluation to the National Science Foundation for Global Recognition. Along with addressing these regulatory issues, the company actively engaged in developing commerce pathways that include state pharmaceutical distribution through State Boards of Pharmacy and offering licensing arrangements for brand-consumer companies. Established in May 2017, CannAssist, headquartered in San Diego, California, with a management team that includes expert scientists, healthcare professionals and product research specialists.  The company’s proprietary CiBiDinol Technology aims to create superior CBD products with higher absorbability, efficacy and longer shelf life. Marketed under the Xceptol brand, CannAssist’s CBD products are sold online through the RangeMe product marketplace and multiple international sales channels throughout Central America, South America, South Africa, the EU, the UK and the Philippines. For more information, visit the company’s website at www.CannAssistInternational.com. NOTE TO INVESTORS: The latest news and updates relating to CNSC are available in the company’s newsroom at https://ibn.fm/CNSC

• Ovarian cancer is a leading cause of death, causes more death than any other female reproductive system cancer
• POAI’s Helomics dedicated to improving clinical decision making for ovarian cancer patients
• Helomics has pioneered testing of drugs on patients’ own tumors to help oncologists individualize treatment options

According to the American Cancer Society, an estimated 21,750 women received a new diagnosis of ovarian cancer this year, and almost 14,000 women will die from the disease (https://ibn.fm/4yfJn). Those numbers make ovarian cancer the fifth-leading cause of cancer deaths in women; ovarian cancer causes more deaths than any other cancer of the female reproductive system. These are the numbers that Predictive Oncology (NASDAQ: POAI) is working to change.

For more than a year, Helomics, a wholly owned subsidiary of POAI, has been working with the University of Pittsburgh School of Medicine (“UPMC”) to study the use of artificial intelligence (“AI”) to improve clinical decision making for ovarian cancer patients (https://ibn.fm/88drd). The project, a joint collaborative agreement with UPMC called CancerQuest2020, kicked off in summer 2019.

The collaboration entails using Helomics’ AI platform and proprietary data to analyze the genomic and drug response profiles of women with ovarian cancer to evaluate predictive value in terms of response and non-response to different treatments.

“Helomics has pioneered the testing of drugs on the patient’s own tumor to help oncologists individualize treatment options — what we call functional precision medicine,” said Helomics chief innovation officer, Dr. Mark Collins. “We believe that by linking both the drug response profile and the genomic profile of the patient’s tumor using a machine learning approach, we can provide ‘multi-omic’ predictive models that will have greater decision-making impact than just genomics alone, which in turn will positively benefit oncologists and their patients.”

According to POAI, the predictive models “embody the knowledge from these profiles to create a ‘computational expert’ or a ‘virtual patient’ that can be queried. Predictive models such as these are also of high value to pharmaceutical companies as they can be used to quickly select patients for clinical trials and assess potential new drugs or biomarkers computationally (‘in silico’) before initiating expensive laboratory experiments. In short, Helomics’ predictive models will save time and money in the search for new targeted therapies” (https://ibn.fm/pFLn0).

Helomics brings to the project data generated from more than 150,000 tumor cases obtained from over 15 years of clinical testing on living patient tumors. That date includes drug response, genomic (mutations), transcriptomic (gene expression) and tissue-omic (tumor pathology) profiles that help predict drug response and outcome.

According to the company, “We have developed a unique technology that combines our clinically validated primary tumor cell assay and drug response data . . . together with proven artificial intelligence (‘AI’) to allow us to test potential drugs against patient tumor cells, much earlier in the drug discovery process. We believe this patient-centric approach will significantly improve the success of translating compounds into the clinic, saving time, cost, and most importantly getting therapies to patients more quickly” (https://ibn.fm/iqjra).

POAI is bringing precision medicine, or tailored medical treatment using the individual characteristics of each patient, to the treatment of cancer. Through its Helomics division, the company leverages its unique, clinically validated patient derived (“PDx”) smart tumor profiling platform to provide oncologists with a roadmap to help individualize therapy. In addition, the company is leveraging artificial intelligence and its proprietary database of over 150,000 cancer cases tumors to build AI-driven models of tumor drug response to improve outcomes for the patients of today and tomorrow.

For more information, visit the company’s website at www.Predictive-Oncology.com.

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

• Pure Extracts upsizes private placement to total 16,900,000 special warrants at price of $0.505.
• PULL also received approval from OTC Markets, is trading on OTC Market under ticker symbol PRXTF.
• Trading under new OTC ticker is “major step forward,” says Company CEO.

Pure Extracts Technologies (CSE PULL) (OTC: PRXTF) (XFRA: A2QJAJ), a plant-based extraction company, has increased its non-brokered private placement offering of special warrants; the original offering was announced on Dec. 16, 2020. The company also received approval from OTC Markets and is now trading on the OTC Market under the ticker symbol PRXTF.

The Company observed that the upsized private placement comprises 16,900,263 special warrants at a price of $0.505, which would result in gross proceeds for the Company of an estimated $8,534,632. The announcement explained that the Company anticipated using the proceeds from the placement for expanding the capacity of its extraction business as well as for general working capital.

Regarding trading on the OTC Market, Pure Extracts’ CEO Ben Nikolaevsky noted that “Trading under the new OTC ticker symbol PRXTF and applying for DTC eligibility is a major step forward in making it materially easier to welcome U.S.-based investors as new shareholders. This is an important step in amplifying our story to a wider audience and to grow our investor base.”

OTC Markets offer developing Canadian companies the opportunity to be publicly traded in the United States at lower cost and complexity than a U.S. exchange listing. Streamlined market standards allow Canadian companies to provide a strong baseline of transparency to inform and engage U.S. investors. To receive approval to trade on the OTC Markets, Canadian companies must be up-to-date in their SEDAR reporting and undergo regular verification and management certifications. Pure Extracts’ shares will continue to trade on the Canadian Securities Exchange (“CSE”) under the symbol ‘PULL’.

These announcements are indicative of Pure Extracts’ focus to strengthen and grow its presence in the cannabis, hemp and functional mushroom sectors as it leverages its expertise in extraction processes (https://ibn.fm/k2wpB). The Company’s forward-thinking strategy aligns with existing infrastructure and includes plans to develop high-bioavailable products and novel delivery methodologies, including tinctures, pills, capsules and edibles. One such venture, initiated in December, is its functional mushroom wellness business, which entails a process through which the active ingredients in mushroom biomass is concentrated into capsules and tinctures.

“Moving into the field of mushroom extractions is an obvious and exciting opportunity to leverage our advanced technology and proven capabilities,” said Nikolaevsky (https://ibn.fm/aP9p2). “We look forward to launching our functional products commercially within the next few months and can’t help but see the similarities to the cannabis sector regarding the pathways to both medical and recreational legalization. I believe our ability to immediately begin working in this burgeoning sector will create immense value for our business, our stakeholders, partners and shareholders alike.”

Headquartered just north of Whistler, British Columbia, Pure Extracts is a publicly listed, plant-based, extraction company that appears ideally positioned to be one of the dominant extraction companies in the rapid development and commercialization of functional mushroom and medicinal psychedelic products.

For more information, visit the company’s website at www.PureExtractsCorp.com.

NOTE TO INVESTORS: The latest news and updates relating to PULL are available in the company’s newsroom at https://ibn.fm/PULL

• Company will initiate a Phase II adult trial for Berubicin this year focused on patients with glioblastoma multiforme
• WPD, a CNS sub-license partner, will be commencing a parallel Phase II adult trial and the first-ever pediatric Berubicin trial
• Additional clinical trials are in the pipeline, including one for the company’s newest drug candidate, WP1244, and its effects on central nervous system tumors

Biopharmaceutical company CNS Pharmaceuticals (NASDAQ: CNSP) recently took part in the H.C. Wainwright Bioconnect 2021 Virtual Conference, which took place January 11-14, 2021. CNS’s CEO John Climaco gave a presentation at the event, discussing how the clinical-stage biopharmaceutical company is developing novel treatments for primary and metastatic cancers of the brain and central nervous system (https://ibn.fm/7zYST).

CNS’s lead drug candidate is Berubicin, an anthracycline that, based on clinical data, can cross the blood-brain barrier in adults and reach the tumor cells of patients with brain cancer. As an organ targeted therapeutic, Berubicin demonstrated one durable complete response (not detectible on imaging) in a Phase I trial completed by Reata Pharmaceuticals, Inc. (NASDAQ: RETA) 14 years ago. CNS currently holds the worldwide exclusive licensing to the Berubicin drug and it recently obtained Investigational New Drug designation for it from the Food and Drug Administration.

In addition to Berubicin, the company’s current developmental pipeline includes a second promising drug candidate, WP1244. Licensed from The University of Texas MD Anderson Cancer Center in the first quarter of 2020, WP1244 is a DNA-binding agent that represents a novel class of potential therapeutics.

WP1244 is designed using anthracycline and distamycin-based scaffolds, creating small molecule agents binding extended sequences of DNA. In vivo testing demonstrated high uptake with WP1244 in the brain and subsequent antitumor activity in orthotopic models of the brain. The drug candidate is believed to be 500 times more potent than daunorubicin in inhibiting tumor cell proliferation. CNS entered into a Sponsored Research Agreement with MD Anderson Cancer Center in May 2020, related to WP1244.

CNS Pharmaceuticals, in partnership with company sublicensee WPD Pharmaceuticals, Inc. (CSE: WBIO) (FSE: 8SV1) currently has several clinical trials in different stages of preparation, including three glioblastoma multiforme (“GBM”) studies for Berubicin, scheduled to begin in Q1 2021. These include a randomized, controlled Phase II trial in the United States and another Phase II in Poland, conducted by WPD. Both these studies will be conducted with adult candidates. WPD will also begin the first-ever Phase I pediatric trial with Berubicin in Poland. Other studies in the pipeline for a future date include a potential Phase I trial for Berubicin with pancreatic and ovarian cancer and lymphoma patients as well as a potential Phase I trial for WP1244 for central nervous system tumors.

The primary focus for Berubicin has been patients with GBM, one of the most aggressive forms of brain cancer currently considered incurable. Each year, nearly 15,000 new GBM patients are being diagnosed in the United States. With the optimal therapy (surgical resection, chemotherapy, radiation), the median survival rate is only 15-23 months. Nearly 100% of GBM tumors recur after first-line therapy.

The Phase II trials for Berubicin in adult candidates are designed to be:

• Adaptive – the trial is designed to allow for modifications based on accumulated data from trial subjects
• Randomized – the trial randomizes which patients receive Berubicin versus the control group, eliminating the bias and increasing statistical significance
• Controlled – a control arm receiving the standard of care to compare the effectiveness of Berubicin against this standard, increasing the statistical significance
• Potentially Pivotal – the trials are designed to provide, pending positive results, the data necessary to support CNS’s request to the FDA for an expedited pathway to further development or approval of Berubicin

CNS believes that Berubicin has the potential to become a standard of care for GBM and other forms of brain cancer. The current first-line therapy includes temozolomide (“TMZ”). Nearly 40% of patients are genetically predisposed to respond to, becoming resistant to the treatment quickly. Berubicin could potentially be a second-line drug in these cases. The remaining 60% of patients may not be affected by TMZ, making Berubicin a potential first choice.

At the close of the presentation, Climaco said the company expects to see the first data for the Phase II trial in Poland reported during the third or fourth quarter of this year.

For more information, visit the company’s website at www.CNSPharma.com

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

• Green Hygienics poised to become most highly certified hemp company in industry to differentiate itself from competition
• Anticipating tightening of regulatory standards, GRYN already achieved FDA registration and USDA/CCOF certification proving highest standards of product quality, transparency and safety
• With certifications to prove high-quality products, Green Hygienics appears ideally positioned to offer growth potential in increasingly quality-aware market

As an innovative technology-driven enterprise, Green Hygienics Holdings (OTCQB: GRYN) is dedicated to delivering the highest operating standards of industrial hemp cultivation and processing, and manufacturing of pharmaceutical-grade bioactive cannabinoids. Poised to bring safe and consistent products to market and thus change the industry’s landscape and enhance consumer confidence, GRYN is committed to becoming the most highly certified hemp company in the industry (https://ibn.fm/GVl6o). Last year was a year of success for Green Hygienics as the company achieved important milestones that lie at the heart of its value proposition. The first is registration with the U.S. Food and Drug Administration, which enhances GRYN’s core mission to provide processing and product safety, transparency and reliability both to consumers and the pharmaceutical industry. The second is the USDA Organic Certification (7 CFR Part 205) issued by the California Certified Organic Farmers, which allows Green Hygienics to cultivate and process post-harvest industrial hemp and supply certified organic hemp products to national and international markets from its Sol Valley Ranch property. With its 824-acre hemp farm, including 400,000 square feet of indoor greenhouse space, GRYN has become the largest single USDA-certified organic hemp farm in North America (https://ibn.fm/R8bLj). Green Hygienics appears ideally positioned to remain on the research-based innovation path and drive new product commercialization fully complaint to USDA and FDA regulatory requirements. The company intends to rationally design and deliver novel fit-for-purpose cannabinoids and targeted bio-delivery technologies, using cutting-edge technology to solve the issues of product stability, pharmacokinetics, biological tissue distribution and systemic bioavailability to improve the lives of billions. With an emerging push in the market as consumers ask for safe and efficacious products while industries such as medical, nutraceutical and pharmaceutical are seeking a secure supply chain, product quality and product associated evidence-based functionality become strong differentiators among medical practitioners and customers. The company that can address these unmet market needs could be well-placed to secure a strategic advantage in the marketplace and Green Hygienics looks poised to achieve precisely that and to become a leader in compliances and capabilities in the hemp and cannabinoid supply marketplace. As GRYN intends to become the most highly certified hemp company in the industry, it presents investors with an opportunity to invest in a company that uniquely positions itself as a trusted source that delivers safe and premium quality products to consumers and to CPG (consumer-packaged-goods) and pharmaceutical companies. With certifications to prove the highest operating standards, Green Hygienics seems well-positioned to offer growth potential in a market that is becoming increasingly quality-aware. For more information, visit the company’s website at www.GreenHygienics.com. NOTE TO INVESTORS: The latest news and updates relating to GRYN are available in the company’s newsroom at http://ibn.fm/GRYN

• Research shows that market for agricultural biopesticides expected to grow rapidly at CAGR of 14.7% until 2025
• MustGrow providing natural plant-based biopesticide solutions for protecting plants from pests and diseases, utilizing the natural defense mechanism of the mustard plant
• Company seems well positioned within biopesticides market expected to achieve fastest growth

The market for agricultural biopesticides is growing rapidly. The latest Markets and Markets report estimated the industry was valued at $4.3 billion in 2020 and is projected to almost double its size in the next five years — reaching $8.5 billion by 2025 and growing at a CAGR of 14.7% during the same period (https://ibn.fm/26NNm). MustGrow Biologics (CSE: MGRO) (OTCQB: MGROF) (FRA: 0C0) is well placed to capitalize on this opportunity, backed by the changing market landscape that increasingly favors natural solutions to protect agricultural crops. MustGrow’s organic biopesticide approach is plant based — harnessing the mustard seed’s natural defense mechanism to control diseases, pests and weeds.

According to the report, the use of “synthetic chemicals can lead to pollution and contamination of the soil as well as can have. . . harmful effects on the food chain.” Because of this, the report observes, there has been increasing awareness of residue-free food and a high interest in biological products.

With the change in eating habits, farmers are pressurized to shift to adopt a sustainable method of farming. Fruit and vegetable cultivation requires more investment, and with the huge infestation in fruits and vegetables both in open fields and green-houses, the demand for biopesticides is increasing. Also, to meet the export demand for residue-free crops, farmers are implementing the use of biopesticide in combination with conventional chemicals. The trend in the consumption of organic crops is also pushing farmers to adopt biopesticides.

Along with a greater awareness of biopesticides has come increasing demand for organic-grown food. “The acreage under organic cultivation for fruits and vegetables is also increasing,” the report noted. “And to achieve the standards prescribed by international exports, farmers are adopting the usage of biopesticides. To combat the harmful effects of synthetic pesticides, the government is taking initiatives in various regions by emphasizing the use of integrated pest management. Strategic developments such as expansions, new product launches, collaborations, and agreements have been adopted by the majority of key players to strengthen the market.”

The report projects that within the whole biopesticides space, the bioinsecticides segment is expected to dominate the market during the forecast period, and the fruits and vegetable segment is expected to achieve the fastest growth. The increasing pest resistance and the resurgence of crops require sustainable solutions amid regulatory ban and phase-out of some of the main ingredients.

Because of their “favorable” properties, bioinsecticides are positioned as an adequate response — they do not leave residues in the products, and they do not harm natural pests’ enemies or the environment. According to the report, the North American region is expected to drive the growth of the international biopesticides market.

The change in market demanding residue-free and organic food combined with the ever-more stringent regulatory standards in the international agricultural food supply chain is pressuring farmers to adopt a sustainable method of farming using biopesticides. As a company that operates in the robust segments of the growing biopesticides space, MustGrow is ideally positioned to benefit from these market forces.

This agriculture biotech company, which is focused on providing natural science-based biological solutions for high-value crops such as fruits and vegetables, appears poised to leverage the growing momentum favoring alternatives to synthetic chemicals. As global agriculture looks to move closer to sustainable ways of boosting yields and crop protection, MustGrow continues to position itself as an essential part of the food landscape of the future with its mustard plant-based biopesticide.

For more information, visit the company’s website at www.MustGrow.ca.

NOTE TO INVESTORS: The latest news and updates relating to MGROF are available in the company’s newsroom at https://ibn.fm/MGROF

• Rapidly growing cannabis market evolving to include diverse clientele seeking unique strains
• PACR uses genetics-first approach to cultivate exclusive high-yield strains with varying cannabinoid profiles
• PACR catalog features 350 tested cultivars, including 50 super-elite strains prized for unique properties

Smoking marijuana decades ago traditionally meant rolling one type of cannabis that was grown outdoors under mostly natural conditions. Decades later, the market has completely transformed to accommodate the needs of savvy consumers who understand different strains and their varying effects. PacRoots Cannabis (CSE: PACR) (OTCQB: PACRF), a Canada-based cannabis company dedicated to producing premium-quality strains and products through a genetics-focused approach, is positioned to benefit from this market shift with roughly 350 tested cultivars in its extensive catalog, which includes 50 super-elite strains prized throughout the industry for their unique therapeutic properties. Marijuana strains are typically differentiated by their color, smell, taste and cannabinoid profile – the latter being the phytochemical composition specific to the plant. Specialized cultivation and strain development is undertaken by many growers seeking to leverage specific properties of the plant in order to produce specialized strains for specific markets—markets which include both medical and recreational users. The result of this innovation in cannabis cultivation has been a boom in branded cannabis strains, evidenced by increased brand recognition among loyal, repeat customers at legal dispensaries (https://ibn.fm/iq8Ca). PACR is positioned to benefit from these emerging markets by providing retailers with high-quality strains tailored for specific uses. The company’s genetics-based approach to cultivation has produced prized strains with varying amounts of tetrahydrocannabinol (“THC”) and cannabidiol (“CBD”) – two of over 140 known cannabinoids in the cannabis plant that can produce different effects on the body. Along with altering the cannabinoid profile of its strains, the company also leverages genetic technology to develop plants that thrive in different climatic conditions for maximum yields each season. PACR has a competitive advantage in the industry through its strategic licensing agreement with Phenome One Corp, a privately-held full-service genetics cannabis company that gives PACR access to one of the largest living genetic cannabis libraries in Canada. This valuable, unparalleled resource has enabled the Company to diversify its product catalog to include hundreds of cultivars and dozens of elite strains offering specialized beneficial characteristics unique to the market. The cannabis market has evolved from small-time dealers on street corners to an entire industry with differentiated products and discerning, knowledgeable consumers. PACR is leveraging this market shift through a genetic-first approach to cultivation that produces first-in-class high-yield strains which appeal to a wide variety of consumers across the rapidly growing legal cannabis market. For more information, visit the company’s website at www.PacRoots.ca. NOTE TO INVESTORS: The latest news and updates relating to PACR are available in the company’s newsroom at http://ibn.fm/PACR

• Imagin Medical Inc. successfully weathered the 2020 pandemic-induced economic challenges and transitioned its surgical visualization product, the i/Blue Imaging System(TM) from the development stage to manufacturing  and has  after
• Imagin’s next stage will be supported by a $3 million convertible note, with the final funding tranche expected to close this quarter
• The i/Blue Imaging System combines the advantages of blue light with advanced optic and light sensors to address the limitations of both white and blue light imaging to help surgeons better visualize and remove cancerous cells. The system uses a contrast agent to highlight the cancer and projects both the white and blue light images side-by-side simultaneously on the surgical monitor
• Bladder cancer is the sixth most prevalent cancer in the U.S., the third most common cancer in men, more than 17,000 deaths are expected in the U.S. this year due to bladder cancer
• Once Imagin obtains final FDA approval and finishes rolling out its product, the company expects to expand its product line by adapting its IP for use with multiple contrast agents for use in other minimally invasive surgeries

Following an unusual series of hardships for North America, as well as the world at large, during the past year, people are beginning to see reasons for optimism that 2021 will deliver better economic news, less political unrest and an overall reversal of the COVID pandemic’s persistently climbing death and disability toll.

Imagin Medical (CSE: IME) (OTCQB: IMEXF), has achieved significant milestones during 2020 despite the obstacles posed by COVID and other adverse factors. Imagin’s strategy has positioned the company for greater strides in the coming year as socio-economic conditions improve.

Imagin’s proprietary i/Blue Imaging System is designed to significantly enhance surgeons’’ability to visualize and remove cancer cells using blue light by combining advanced optics and light sensors with a contrast imaging agent. A key feature is the system’s adaptability to almost any scope already in use by hospitals and surgical centers.

But the company was compelled to cut salaries and reduce expenses in all areas of the business during 2020 in order to extend its financial runway for duration of the pandemic, while also transitioning to online meeting technology that better enabled Imagin to safeguard the health and wellbeing of its employees.

Despite the difficulties, Imagin was able to transition its product from the development stage to manufacturing — contracting with Lighthouse Imaging, an FDA registered and ISO 13485:2016-certified manufacturer. The contract will help propel Imagin toward completion of its final pre-production stage and finalize test parameters that meet exacting FDA requirements for live-use surgical imaging equipment., according to a news release issued by the company (https://ibn.fm/Th7Nr).

“Our relationship with Lighthouse Imaging marks a new stage in the company’s progress,” Imagin President and CEO Jim Hutchens stated. “We anticipate 2021 to be a breakout year with emphasis on manufacturing and the FDA process.”

The product preparation for broad manufacturing, as well as FDA approval and marketing procedures, will be funded largely by a $3 million convertible note undertaken by Imagin during the final months of 2020. The company has closed on the first of four tranches and expects to execute the final tranche this quarter, according to the news release.

Imagin will also work to develop expanding support from the medical community, in part through its participation at the 2021 American Urology Association (“AUA”) annual meeting. Imagin considers the AUA conference to be very significant marketing and networking opportunity that, much to their frustrations, was cancelled last year due to the pandemic (https://ibn.fm/gvrX1).

Imagin’s current technological approach is to help combat bladder cancer during minimally invasive surgery with advanced imaging abilities. Bladder cancer is the fourth most common cancer in men and one that is expected to directly result in more than 17,000 deaths this year in the United States, with similar numbers expected for 2021 (https://ibn.fm/R864t). Providing more precise visualization than white light, blue light cystoscopy infuses the bladder with a contrast agent that highlights the contours of the cancer. To resect, however, surgeons must use the real-time white light image, requiring them to switch back and forth to locate and then remove the cancer. The i/Blue Imaging System provides the option to display, in real-time, the white and blue light images side-by-side simultaneously, eliminating the need to switch back and forth resulting in a more efficient and effective procedure.

Eventually, Imagin expects to expand its IP for use with other contrast agents and minimally invasive surgeries, such as laparoscopic (general and gynecological), colorectal and thoracic interventions.

For more information, visit the company’s website at www.ImaginMedical.com.

NOTE TO INVESTORS: The latest news and updates relating to IMEXF are available in the company’s newsroom at https://ibn.fm/IMEXF